- Home
- OKUR vs CLGN Comparison
OKUR vs CLGN Comparison
Compare OKUR & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- CLGN
- Stock Information
- Founded
- OKUR 2011
- CLGN 2004
- Country
- OKUR United States
- CLGN Israel
- Employees
- OKUR N/A
- CLGN N/A
- Industry
- OKUR
- CLGN Industrial Specialties
- Sector
- OKUR
- CLGN Health Care
- Exchange
- OKUR NYSE
- CLGN Nasdaq
- Market Cap
- OKUR 34.9M
- CLGN 37.4M
- IPO Year
- OKUR N/A
- CLGN N/A
- Fundamental
- Price
- OKUR $1.92
- CLGN $1.82
- Analyst Decision
- OKUR Strong Buy
- CLGN Strong Buy
- Analyst Count
- OKUR 4
- CLGN 2
- Target Price
- OKUR $32.25
- CLGN $12.50
- AVG Volume (30 Days)
- OKUR 66.2K
- CLGN 12.5K
- Earning Date
- OKUR 05-06-2025
- CLGN 05-28-2025
- Dividend Yield
- OKUR N/A
- CLGN N/A
- EPS Growth
- OKUR N/A
- CLGN N/A
- EPS
- OKUR N/A
- CLGN N/A
- Revenue
- OKUR N/A
- CLGN $515,000.00
- Revenue This Year
- OKUR N/A
- CLGN $2,177.67
- Revenue Next Year
- OKUR N/A
- CLGN $56.52
- P/E Ratio
- OKUR N/A
- CLGN N/A
- Revenue Growth
- OKUR N/A
- CLGN N/A
- 52 Week Low
- OKUR $1.98
- CLGN $1.82
- 52 Week High
- OKUR $20.00
- CLGN $6.75
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- CLGN 23.18
- Support Level
- OKUR N/A
- CLGN $2.00
- Resistance Level
- OKUR N/A
- CLGN $2.40
- Average True Range (ATR)
- OKUR 0.00
- CLGN 0.21
- MACD
- OKUR 0.00
- CLGN -0.01
- Stochastic Oscillator
- OKUR 0.00
- CLGN 3.59
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.